Company news: Chelsea Therapeutics, iHealth

Share this article:
Biopharma Chelsea Therapeutics announced Tuesday it was clearing house and replacing its CEO. The shakeups include the resignation of founder, president and CEO Simon Pedder. VP Joseph Oliveto will step in as interim President and CEO. The company said in a statement that the changes will also include slashing headcount and evaluating “strategic options for the company.” The eight-year-old firm has also scuttled its pipeline and said it will be focusing on getting authorization for its drug Northera (droxidopa), a treatment for symptomatic neurogenic orthostatic hypotension.

The FDA granted 501(k) approval for iHealth's bluetooth blood pressure monitor, mobihealth reported Tuesday. The blood pressure device, which debuted at the June Pepcom Digital Experience, works in two ways: it uses a wrist wrap instead of a bicep wrap and channels the reading to an iHealth app that can be used with iOS devices. The monitor records heart rate, pulse waves and blood pressure numbers and can tally historical blood pressure readings.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.